Applied DNA to Webcast 2019 Annual Stockholders’ Meeting
10 May 2019 - 7:00PM
Business Wire
Applied DNA Sciences, Inc. (NASDAQ: APDN), will hold its 2019
Annual Meeting of Stockholders on Thursday, May 16, 2019. On that
date, the company will provide an audio-only live webcast of the
meeting beginning at 10:00 AM ET. Slide presentations accompanying
the webcast will be available for download at that time on the
‘Events and Presentations’ portion of the ‘Investors’ page to the
company’s website.
To register for the webcast on May 16, please visit:
https://services.choruscall.com/links/apdn190516.html
A telephonic replay of the Meeting will be available through
5:00 PM ET on Thursday, May 30, 2019:
- Replay dial-in: 1-877-344-7529
- International replay:
1-412-317-0088
- Access code: 10130086
An archived video bundle of the Meeting will be made available
within 48 hours of the Meeting on the ‘Events and Presentations’
portion of the ‘Investors’ page to the company’s website.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and pre-clinical nucleic acid-based
therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN, and
warrants are listed under the symbol APDNW.
Forward Looking Statements
The statements made by Applied DNA in this press release may be
"forward-looking" in nature within the meaning of the Private
Securities Litigation Act of 1995. Forward-looking statements
describe Applied DNA's future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of
risks and uncertainties, many of which are beyond the control of
Applied DNA including the substantial doubt relating to the
Company’s ability to continue as a going concern. Actual results
could differ materially from those projected due to its history of
net losses, limited financial resources, limited market acceptance,
the uncertainties inherent in research and development, future
clinical data and analysis, including whether any of Applied DNA’s
product candidates will advance further in preclinical research or
clinical trial process, including receiving clearance from the U.S.
Food and Drug Administration or equivalent foreign regulatory
agencies to conduct clinical trials and whether and when, if at
all, they will receive final approval from the U.S. FDA or
equivalent foreign regulatory agencies, shifting enforcement
priorities of US federal laws relating to cannabis, ability to
maintain its NASDAQ listing, and various other factors detailed
from time to time in Applied DNA's SEC reports and filings,
including our Annual Report on Form 10-K filed on December 18, 2018
and our subsequent quarterly reports on 10-Q filed on February 7,
2019 and May 9, 2019, and other reports we file with the SEC, which
are available at www.sec.gov. Applied DNA undertakes no obligation
to update publicly any forward-looking statements to reflect new
information, events or circumstances after the date hereof to
reflect the occurrence of unanticipated events, unless otherwise
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190510005027/en/
Investors: Sanjay M. Hurry, LHA Investor Relations,
212-838-3777, shurry@lhai.comWeb:
www.adnas.comTwitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2024 to May 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From May 2023 to May 2024